Form 4 for SPRY ARS Pharmaceuticals, Inc.
Accepted 2025-02-04 00:00:00 ET · period of report 2025-02-03 · accession 0001415889-25-002955 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-02-04 | 2025-02-03 | SPRY | Shawver Laura | Dir | M - OptEx | $4.54 | +50.0K | 219.4K | +30% | +$227.1K |
| D | 2025-02-04 | 2025-02-03 | SPRY | Shawver Laura | Dir | S - Sale+OE | $12.31 | -50.0K | 210.3K | -19% | -$615.5K |
| DM | 2025-02-04 | 2025-02-03 | SPRY | Shawver Laura | Dir | M - OptEx | $0.00 | -50.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-03 | M | A | 40,936 | $4.85 | 260,346 | D | — | — | |
| 2 | Common | Common Stock | 2025-02-03 | S | D | 50,000 | $12.31 | 210,346 | D | — | — | (F2) The weighted average sale price for the transaction reported was $12.3113 and the range of prices were between $11.9732 and $12.76. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| 3 | Common | Common Stock | 2025-02-03 | M | A | 9,064 | $3.15 | 219,410 | D | — | — | |
| 4 | Derivative | Stock Option (Right to Buy) | 2025-02-03 | M | D | 40,936 | $0.00 | 124,064 | D | $4.85 · — to 2032-01-31 | 40,936 Common Stock | (F3) Immediately exercisable. |
| 5 | Derivative | Stock Option (Right to Buy) | 2025-02-03 | M | D | 9,064 | $0.00 | 0 | D | $3.15 · — to 2032-05-01 | 9,064 Common Stock | (F3) Immediately exercisable. |